Cannabidiol inhibits human brain tumor cell migration through a cannabinoid receptor-independent mechanism

We evaluated the flexibility of cannabidiol (CBD) to impair the migration of growth cells stirred by conditioned medium. CBD caused concentration-dependent inhibition of the migration of U87 brain tumour cells, quantified in a very Boyden chamber. Since these cells specific each cannabinoid CB1 and CB2 receptors within the membrane, we have a tendency to additionally evaluated their engagement within the antimigratory impact of CBD. The inhibition of cell wasn’t antagonized either by the selective cannabinoid receptor antagonists SR141716 (CB1) and SR144528 (CB2) or by pretreatment with respiratory disease poison, indicating no involvement of classical cannabinoid receptors and/or receptors coupled to Gi/o proteins. These results reinforce the proof of antitumoral properties of CBD, demonstrating its ability to limit growth invasion, though the mechanism of its pharmacologic effects remains to be processed.



Cannabinoids, the active elements of cannabis, and their derivatives, have a good spectrum of pharmacologic effects exerted through specific semipermeable membrane G-protein-coupled receptors. 2 cannabinoid receptors, CB1 and CB2, are cloned and characterised from class tissues. Cannabinoids induce the inhibition of adenylate cyclases, influence ionic channels, and stimulate extracellular-signal-regulated enzyme (ERK), c-Jun N-terminal enzyme, and p38 mitogen-activated supermolecule enzyme, indicating that they’ll play a general role within the cell survival or death call.

Numerous recent reports state that cannabinoids inhibit the viability of assorted sorts of cancer cells in vitro and in vivo. Cannabinoids induce necrobiosis of malignant brain tumor cells, that is, from the foremost common primary cerebral neoplasm in adults. However, the hallucinogenic effects of those compounds limit their medicative use.

In a previous work, we have a tendency to incontestable that the nonpsychoactive cannabinoid compound, cannabidiol (CBD), will limit brain tumor cell growth in vitro or in vivo, by inducement programmed death. However, the characteristic diffuse infiltrative growth of gliomas makes surgical removal not possible and well complicates the clinical management of those patients.

In general, neoplasm cell invasion may be a complicated method involving adhesion to molecules of the animate thing matrix, degradation of matrix element, and later active neoplasm cell locomotion (migration). Therefore, associate understanding of the capability of CBD to forestall brain tumor cell migration would be vital and will in all probability improve its use as a possible antitumoral compound.

The cannabinoids have complicated effects on cell migration, stimulating or inhibiting counting on the cell sort studied. very little is thought concerning their action on neoplasm cell motility. Anandamide inhibits the migration of human colon cancer cells (SW480) through a CB1-dependent mechanism. In distinction, 2-AG will increase the migration of HL-60 cells, and murine chronic myelocytic leukemia cells Since CBD’s effects on malignant brain tumor cell migration haven’t been investigated however, we have a tendency to investigated however this compound influences the motility of human brain tumor cells, and additionally thought-about the pharmacologic viewpoint, assessing the role of cannabinoid receptors CB1 and CB2.


Effects of cannabinoid receptor antagonists on CBD-induced inhibition of cell migration

Most of the consequences of cannabinoids on the central system represented to date ar believed to be exerted through the cannabinoid receptor. to see whether or not CBD-induced inhibition of cell migration was obsessed on the stimulation of those receptors, 1st we tend to checked the presence of the receptors in our cell lines.

There are results of immunoblot experiments for CB1 and CB2 receptors. one band of roughly 59 kDa mass was obtained for U87 cells, comparable the band determined in murine brain tumor cells C6 and human brain tumor cell line U373 used as positive management, wherever CB1 have already been incontestible. The expression of the cannabinoid receptor CB2 in human brain tumor cells, with a mass of roughly 40 kDa, that is comparable CB2 receptors within the spleen that categorical 2 forms differing in mass probably owing to totally different glycosylated sorts of the receptors.


Glioma Cells

Threatening gliomas are exceptionally invading, proliferative tumors. Glioma cells take after a trademark example of development, attacking the adjoining ordinary mind structures and encompassing extensive veins. Restraining relocation is along these lines a fundamental step towards enhancing the visualization of patients with threatening gliomas. In a past study, we showed that CBD, a nonpsychotropic subsidiary of pot, impeded the feasibility of human glioma cell lines U87 and U373 in vitro and in vivo, proposing its potential restorative utilization.

The present study shows, surprisingly, that CBD can hinder the movement of U87 human glioma cells in vitro. The cannabinoids’ consequences for cell relocation have as of now been accounted for, in spite of the fact that the principle studies were on resistant cells or endothelial cells, coming about once in a while in clashing information relying upon the cell sort. Incitement of the CB2 receptor by the endocannabinoid 2-AG was accounted for to expand the relocation of HL60 and mouse microglia. Interestingly, THC or the manufactured agonist CP-55,940 hindered macrophage relocation, including both receptors, CB1 and CB2. Anandamide has likewise been portrayed as having the capacity to repress the movement of SW480 colon carcinoma cells.

Here, we found that CBD created fixation related restraint of glioma cell relocation in a scope of fixations beginning from 0.01 up to 9 μm, which did not influence cell reasonability, as we have officially reported. In a first endeavor to clear up the system of activity of CBD, we examined whether the restraint of tumor cell movement was because of the traditional cannabinoid receptors. Neither the CB1 rival SR141716 nor the CB2 foe SR144528 kept the cell relocation hindrance because of CBD. Likewise, the blend of the two cannabinoid rivals or the TRPV1 receptor rival capsazepine neglected to estrange the inhibitory impacts of CBD, fortify our past information on the antiproliferative impacts of CBD that came about free of cannabinoid and vanilloid receptors.

The part of cannabinoid receptors in CBD’s pharmacological impacts is at any rate disputable. Tying studies have demonstrated to it could tie to cannabinoid receptors, however in our pharmacological study, the particular adversaries did not piece CBD’s belongings in vitro. Since the presence of a third sort of cannabinoid receptor has been recommended to which CBD could possibly tie, with a perspective to barring any collaboration with Gi/o-coupled receptors, we assessed the impact of CBD on cell relocation likewise in the vicinity of PTX which, nonetheless, was not able to avert CBD-instigated restraint, implying that CBD does not act through cannabinoid and/or different receptors coupled to Gi/o proteins. These information are in accordance with our past results about the proapoptotic impact of CBD on human glioma cells, which was not identified with its cooperation with cannabinoid receptors.

Since CBD has been accounted for to invigorate mouse microglia BV-2 cell relocation through potential tying with a still not completely portrayed receptor named ‘endothelial receptor touchy to Ab-CBD, we could estimate that CBD’s impact in glioma may be because of a collaboration with a comparative kind of receptor indicating opposite agonist properties.


All in all, the present study illustrates, interestingly, that CBD can hinder the movement of tumoral cells. Despite the fact that the component of this activity is not clear right now, we can reject any engagement of traditional cannabinoid receptors and/or Gi/o-coupled receptors. Our information further bolster the utilization of cannabinoids as antimetastatic medications as already exhibited for met-fluoro-anandamide on rodent thyroid growth cell. This antimigratory property, together with the known antiproliferative and apoptotic highlights of CBD, reinforce the proof for its utilization as a potential antitumoral operato



Your Name (required)

Your Email (required)


Your Message